Related Experiment Video
Updated: Jul 17, 2025

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
Published on: February 21, 2025
Emerging cellular and immunotherapies for systemic sclerosis: from mesenchymal stromal cells to CAR-T cells and
Alain Lescoat1,2, Hiroshi Kato3, John Varga3
1University of Rennes CHU Rennes, Inserm, EHESP, Irset -Institut de Recherche en Santé, Environnement et Travail-UMRS.
Purpose Of Review:
Although two targeted therapies have received recent approval for systemic sclerosis (SSc)-associated interstitial lung disease, they do not show major disease-modifying activity, highlighting the need for novel therapies and innovative paradigms. To that end, cellular therapies may represent a new opportunity for the treatment of SSc. The purpose of this review is to provide an up-to-date overview of emerging cell-based disease-modifying therapies in SSc.
Recent Findings:
Initial small studies in patients with severe refractory systemic lupus erythematosus (SLE) using engineered regulatory cells show promising results. CD19-directed CAR-T have shown promising results in one case report of refractory diffuse cutaneous SSc patients. T cells engineered to express a chimeric autoantibody receptor (CAAR-T cells) may be even more relevant via the specific elimination of auto-reactive B cells. Targeting pro-fibrotic or senescence-related pathways may also constitute promising approaches in SSc.
Summary:
Building on the classification of the clinical phenotype and prediction of clinical trajectory based on individual patients' autoantigen and/or autoantibody profile, cellular therapies targeting the same autoantigen or related autoreactive cells may represent an unprecedented opportunity to implement personalized medicine in SSc.
Insights
Emerging cellular therapies offer new hope for treating systemic sclerosis (SSc)-associated interstitial lung disease. These innovative treatments, including engineered T cells, show promise for disease modification and personalized medicine approaches in SSc.
Area of Science:
- Immunology
- Cellular Therapy
- Rheumatology
Background:
- Systemic sclerosis (SSc)-associated interstitial lung disease (ILD) lacks major disease-modifying therapies despite recent approvals.
- Novel treatment paradigms are essential for managing SSc-ILD.
- Cellular therapies present a promising avenue for SSc treatment.
Purpose of the Study:
- To review emerging cell-based disease-modifying therapies for SSc.
- To provide an updated overview of the latest advancements in SSc cellular therapy.
Main Methods:
- Review of current literature on cellular therapies in SSc and related autoimmune diseases.
- Analysis of engineered T cell approaches, including CAR-T and CAAR-T cells.
- Exploration of targeting pro-fibrotic and senescence pathways.
Main Results:
- Engineered regulatory cells show promise in refractory systemic lupus erythematosus (SLE).
- CAR-T cells demonstrated positive results in a case report of refractory diffuse cutaneous SSc.
- CAAR-T cells offer potential for eliminating auto-reactive B cells in SSc.
- Targeting pro-fibrotic or senescence pathways are also promising approaches.
Conclusions:
- Cellular therapies hold significant potential for disease modification in SSc.
- Personalized medicine in SSc can be advanced by targeting autoantigens or autoreactive cells.
- Further research into cellular therapies is warranted for SSc treatment.
Related Concept Videos
Tumor Immunotherapy
Mesenchymal Stem Cells
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Autoimmune Disorders
Concept and Mechanism of Autoimmune Diseases
The immune...
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
